Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834 Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR201504000771349 Date of Approval: 17/02/2014
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title Preeclampsia Intervention with Esomeprazole (PIE) trial
Official scientific title The Preeclampsia Intervention with esomeprazole (PIE)trial: a double blind randomised, placebo-controlled trial to treat early onset severe preeclampsia
Brief summary describing the background and objectives of the trial Preeclampsia is one of the most serious complications of pregnancy, globally responsible for 60,000 maternal deaths per year, and far more fetal deaths. Once diagnosed, there are no drugs that can slow disease progression and delivery is the only cure. Esomeprazole is a proton pump inhibitor commonly used for the treatment of gastric acid-related disorders. These medications have been widely used in pregnancy for these indications and maternal and fetal safety is well established We have generated preclinical data to suggest proton pump inhibitors may be candidate therapeutics to treat preeclampsia. We found proton pump inhibitors: 1. Potently decrease the release of soluble endoglin (sEng) and soluble Fms-like Tyrosine Kinase 1 (sFlt-1) from both primary placental tissue and primary endothelial cells in vitro. These are anti-angiogenic factors released from the placenta and thought to play a central role in the pathogenesis of preeclampsia. 2. Potently upregulate heme oxygenase-1, a potent ¿cytoprotective¿ molecule in the placenta. 3. Potently decrease endothelial dysfunction in in vitro assays. In South Africa, severe pre-eclampsia is extremely common, and limited access to tertiary neonatal care means that severe pre-eclampsia is managed conservatively with close surveillance until 34 weeks gestation. This creates a unique opportunity to test our hypothesis that esomeprazole could slow disease progression in severe early onset pre-eclampsia, allowing the fetus to safely gain gestation. If proven, it could be the first successful treatment for preeclampsia. Objectives: To examine whether 40mg of esomeprazole given to women with severe ealry onset preeclampsia can 1.prolong gestation for 5 days 2.significantly decrease sFlt and/or sEng 3. improve maternal and fetal outcomes 4. be tolerated by baby and mother and is safe
Type of trial RCT
Acronym (If the trial has an acronym then please provide) PIE
Disease(s) or condition(s) being studied Preeclampsia,Pregnancy and Childbirth
Sub-Disease(s) or condition(s) being studied
Purpose of the trial Treatment: Drugs
Anticipated trial start date 01/05/2015
Actual trial start date 27/01/2016
Anticipated date of last follow up 06/07/2017
Actual Last follow-up date 22/06/2017
Anticipated target sample size (number of participants) 120
Actual target sample size (number of participants) 120
Recruitment status Completed
Publication URL http://bmjopen.bmj.com/content/5/10/e008211.abstract
Secondary Ids Issuing authority/Trial register
nil known NHREC 3649
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously Randomised Stratified for gestational age using blocks of 4 to 6 Central randomisation Masking/blinding used
Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously Randomised Stratified for gestational age using blocks of 4 to 6 Central randomisation Masking/blinding used
Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously Randomised Stratified for gestational age using blocks of 4 to 6 Central randomisation Masking/blinding used Care giver/Provider,Outcome Assessors,Participants
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group Esomeprazole 40 mg daily per os Until delivery (0 to 8 weeks) Esomeprazole 60
Control Group Control placebo tablet daily Until delivery (0 to 8 weeks) Control 60 Placebo
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
Diagnosis of preeclampsia, super-imposed preeclampsia unclassified or proteinuric hypertension AND all of the following Gestational age between 26 + 0 weeks and 31 + 6 weeks Estimated fetal weight by ultrasound between 500gm and 2000gm, (if gestation is not certain) Singleton pregnancy The managing clinicians have made the initial assessment at initial diagnosis to proceed with expectant management and that delivery is not expected within 48 hours The managing clinician and neonatologist believe that the fetus could be potentially delivered viable No suspicions of a major fetal anomaly The mother must be able to understand the information provided, with the use of an interpreter if needed The mother must be able to give informed consent Patient will be admitted to hospital for expectant management and standardized care Patient is unable or unwilling to give consent Established fetal compromise that necessitates delivery The presence of any of the following at presentation: 1.Eclampsia 2.Severe hypertension (systolic blood pressure greater than 170 or diastolic blood pressure greater than 110) that cannot be controlled with antihypertensive medication within 48 hours of admission 3.Cerebrovascular event 4.Severe renal impairment needing delivery 5.Haemolysis 6.Signs of left ventricular failure (pulmonary oedema requiring treatment; oxygen saturations of less than 95% caused by left sided heart failure) 7.Disseminated intravascular coagulation 8.Platelet count at presentation less than 50x109 (platelet aggregation excluded) 9.Haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome defined as a platelet count less than 100 × 109/L, aspartate aminotransferase greater than 40 ¿/L, alanine aminotransferase greater than 53 ¿/L and haemolysis as demonstrated by lactate dehydrogenase > 350 ¿/L or haemolysis on a peripheral blood smear or a raised haptoglobin level) 10.Liver transaminases >300IU/L; 11.Liver haematoma 12.Fetal distress on cardiotocography 13.Severe ascites on ultrasound Contraindications for expectant management of pre-eclampsia Current use of a proton pump inhibitor Contraindications to the use of a proton pump inhibitor Previous hypersensitivity reaction to a proton pump inhibitor Current use of a drug that may be affected by a proton pump inhibitor: warfarin, ketoconazole, voriconazole, atazanavir, nelfinavir, saquinavir, digoxin, St John¿s Wort, rifampin, cilostazol, diazepam, tacrolimus, erlotinib, methotrexate and clopidogrel. 16 Year(s) 50 Year(s) Female
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 07/11/2014 Health Research Ethics Committee Stellenbosch University
Ethics Committee Address
Street address City Postal code Country
Tygerberg Hospital, Francie van Zyl Drive Cape Town 7505 South Africa
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome Prolongation of gestation At delivery (measured from enrolment to time of delivery
Secondary Outcome Improved fetal, neonatal and maternal outcomes Delivery
Secondary Outcome Serum sFlt-1 and sEng levels Twice weekly Delivery
Secondary Outcome Safety and tolerability of esomeprazole Delivery
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Tygerberg Hospital Francie Van Zijl Cape Town 7505 South Africa
FUNDING SOURCES
Name of source Street address City Postal code Country
Melbourne University 163 Studley Road, Heidelberg Melbourne 3084 Australia
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Secondary Sponsor Discovery Foundation South Africa Charities/Societies/Foundation
Secondary Sponsor South African Medical Association South Africa Charities/Societies/Foundation
Primary Sponsor University of Stellenbosch Francie van Zijlrylaan, Parow Cape Town 7500 South Africa University
COLLABORATORS
Name Street address City Postal code Country
Stephen Tong Melbourne University and Mercy Hospital for Women, 163 Studley Road, Heidelverg Melbourne 3084 Australia
Susan Walker Melbourne University and Mercy Hospital for Women, 163 Studley Road, Heidelverg Melbourne 3084 Australia
Gerhard Theron Stellenbosch University, Tygerberg Hospital, Francie van Zijl Drive, Parow Cape Town 7505 South Africa
Catherine Cluver Stellenbosch University, Tygerberg Hospital, Francie van Zijl Drive, Parow Cape Town 7505 South Africa
Ben Mol The Robinson Institute, School of Paediatrics and Reproductive Health, University of Adelaide Adelaide 5000 Australia
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator Catherine Cluver cathycluver@hotmail.com 27823210298 Stellenbosch University and Tygerberg Hospital, Francie van Zijl Drive, Parow
City Postal code Country Position/Affiliation
Cape Town 7505 South Africa Consultant Obstetrician and Gynaecologist
Role Name Email Phone Street address
Public Enquiries Catherine Cluver cathycluver@hotmail.com +27823210298 Stellenbosch University and Tygerberg Hospital, Francie van Zijl Drive, Parow
City Postal code Country Position/Affiliation
Cape Town 7505 South Africa Consultant Obstetrician and Gynaecologist
Role Name Email Phone Street address
Scientific Enquiries Catherine Cluver cathycluver@hotmail.com +27823210298 Stellenbosch University and Tygerberg Hospital, Francie van Zijl Drive, Parow
City Postal code Country Position/Affiliation
Cape Town 7505 South Africa Consultant Obstetrician and Gynaecologist
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
URL Results Available Results Summary Result Posting Date First Journal Publication Date
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information